Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The experimental treatment consists in the application of a therapeutic strategy with post
Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving
1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation
for Myeloid Malignancies.